Abstract
Dopamine agonists are the first line of therapy for prolactinomas, with high rates of biochemical control and tumour shrinkage. Toxicity is considered to be low and manageable by switching of agents and dose reduction. Dopamine agonist-induced impulse control disorders are well described in the neurology setting, but further data are required regarding this toxicity in prolactinoma patients. We performed a multicenter retrospective cohort study of eight men with prolactinomas and associated central hypogonadism. The eight men had no prior history of psychiatric disease, but each developed disruptive hypersexuality whilst on dopamine agonist therapy at various doses. Cabergoline, bromocriptine and quinagolide were all implicated. Hypersexuality had manifold consequences, including relationship discord, financial loss, reduced work performance, and illicit activity. We hypothesise that this phenomenon is due to synergy between reward pathway stimulation by dopamine agonists, together with rapid restoration of the eugonadal state after prolonged hypogonadism. We refer here to this distinct drug toxicity as ‘dopa-testotoxicosis’. Given the profound impact in these patients and their families, cessation of dopamine agonists should be considered in men who develop hypersexuality, and pituitary surgery may be required to facilitate this. Awareness of this distinct impulse control disorder should enable further research into the prevalence, natural history and management of dopa-testotoxicosis. The condition is likely under-reported due to the highly personal nature of the symptoms and we suggest a simple written questionnaire to screen for hypersexuality and other behavioural symptoms within the first six months of dopamine agonist treatment.
Similar content being viewed by others
References
A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91(12), 4769–4775 (2006)
A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.) 72(3), 377–382 (2010)
A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, G. Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89(4), 1704–1711 (2004)
M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27(5), 485–534 (2006)
L. Sibal, P. Ugwu, P. Kendall-Taylor, S.G. Ball, R.A. James, S.H. Pearce, K. Hall, R. Quinton, Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5(4), 243–246 (2002)
J.J. Pinzone, L. Katznelson, D.C. Danila, D.K. Pauler, C.S. Miller, A. Klibanski, Primary medical therapy of micro-and macroprolactinomas in men. J. Clin. Endocrinol. Metab. 85(9), 3053–3057 (2000)
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 331(14), 904–909 (1994)
J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers, J. Mockel, G. Lamberigts, P. Petrossians, P. Coremans, C. Mahler, A. Stevenaert, J. Verlooy, C. Raftopoulos, A. Beckers, Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84(7), 2518–2522 (1999)
D.J. Vinkers, N.J. van der Wee, A case of mania after long-term use of quinagolide. Gen. Hosp. Psychiatry 29(5), 464 (2007)
T.J. Moore, J. Glenmullen, D.R. Mattison, Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med. 174(12), 1930–1933 (2014)
C.D. Andela, M. Scharloo, A.M. Pereira, A.A. Kaptein, N.R. Biermasz, Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18(5), 752–776 (2015)
M. De Rosa, S. Zarrilli, G. Vitale, C. Di Somma, F. Orio, L. Tauchmanova’, G. Lombardi, A. Colao, Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J. Clin. Endocrinol. Metab. 89(2), 621–625 (2004)
I. Bancos, M.R. Nannenga, J.M. Bostwick, M.H. Silber, D. Erickson, T.B. Nippoldt, Impulse control disorders in patients with dopamine agonist‐treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study. Clin. Endocrinol. (Oxf.) 80(6), 863–868 (2014)
A.P. Athanasoulia, C. Sievers, M. Ising, A.C. Brockhaus, A. Yassouridis, G.K. Stalla, M. Uhr, Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur. J. Endocrinol. 167(3), 327–335 (2012)
M. Barake, A.E. Evins, L. Stoeckel, G.N. Pachas, L.B. Nachtigall, K.K. Miller, B.M. Biller, N.A. Tritos, A. Klibanski, Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 17(2), 150–156 (2014)
J. Martinkova, L. Trejbalova, M. Sasikova, J. Benetin, P. Valkovic, Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin. Neuropharmacol. 34(5), 179–181 (2011)
H. Falhammar, J.Y. Yarker, Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med. J. Aust. 190(2), 97 (2009)
A. Gupta, R.S. Zimmerman: Hypersexuality in cabergoline-treated prolactinoma. Paper presented at the 93rd Annual Meeting of the Endocrine Society, 2011
M.R. Nannenga, P.J. Tebben, T.B. Nippoldt: Development of impulse control disorders in patients with dopamine agonist treated prolactinomas: a case series. Paper presented at the 93rd Annual Meeting of the Endocrine Society, 2011
R. Sandyk, M. Bergsneider, R.P. Iacono, Acute psychosis in a woman with a prolactinoma. Int. J. Neurosci. 37(3–4), 187–190 (1987)
Acknowledgments
The authors would like to thank Associate Professor Sanghamitra Guha and Dr Anthony Roberts who provided clinical data for two patients. This study was in part supported by the Magnus Bergvalls Foundation, Karolinska Institutet and Stockholm County Council.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval
A waiver of informed consent was approved by the Royal Adelaide Hospital Human Research Ethics Committee in accordance with the National Health and Medical Research Council guidelines.
Rights and permissions
About this article
Cite this article
De Sousa, S.M., Chapman, I.M., Falhammar, H. et al. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 55, 618–624 (2017). https://doi.org/10.1007/s12020-016-1088-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1088-1